176 related articles for article (PubMed ID: 7639798)
1. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.
Manicourt DH; Fujimoto N; Obata K; Thonar EJ
Arthritis Rheum; 1995 Aug; 38(8):1031-9. PubMed ID: 7639798
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis.
Manicourt DH; Fujimoto N; Obata K; Thonar EJ
Arthritis Rheum; 1994 Dec; 37(12):1774-83. PubMed ID: 7986224
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest.
Manicourt DH; Poilvache P; Nzeusseu A; van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 1999 Sep; 42(9):1861-9. PubMed ID: 10513800
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis.
Yoshihara Y; Obata K; Fujimoto N; Yamashita K; Hayakawa T; Shimmei M
Arthritis Rheum; 1995 Jul; 38(7):969-75. PubMed ID: 7612046
[TBL] [Abstract][Full Text] [Related]
6. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
7. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
8. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate.
Manicourt DH; Triki R; Fukuda K; Devogelaer JP; Nagant de Deuxchaisnes C; Thonar EJ
Arthritis Rheum; 1993 Apr; 36(4):490-9. PubMed ID: 8457224
[TBL] [Abstract][Full Text] [Related]
9. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
[TBL] [Abstract][Full Text] [Related]
10. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis.
Maeda S; Sawai T; Uzuki M; Takahashi Y; Omoto H; Seki M; Sakurai M
Ann Rheum Dis; 1995 Dec; 54(12):970-5. PubMed ID: 8546529
[TBL] [Abstract][Full Text] [Related]
11. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
Brennan FM; Browne KA; Green PA; Jaspar JM; Maini RN; Feldmann M
Br J Rheumatol; 1997 Jun; 36(6):643-50. PubMed ID: 9236673
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K
Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
14. Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patella.
Väätäinen U; Lohmander LS; Thonar E; Hongisto T; Agren U; Rönkkö S; Jaroma H; Kosma VM; Tammi M; Kiviranta I
Osteoarthritis Cartilage; 1998 Mar; 6(2):115-24. PubMed ID: 9692066
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Miyazaki K; Iwata H
J Rheumatol; 1999 Jan; 26(1):34-40. PubMed ID: 9918237
[TBL] [Abstract][Full Text] [Related]
16. Serum metalloproteinases and their inhibitors: markers for malignant potential.
Baker T; Tickle S; Wasan H; Docherty A; Isenberg D; Waxman J
Br J Cancer; 1994 Sep; 70(3):506-12. PubMed ID: 8080738
[TBL] [Abstract][Full Text] [Related]
17. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
[TBL] [Abstract][Full Text] [Related]
18. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik B; Skowronski J; Chwiecko J
Rheumatology (Oxford); 2002 Jan; 41(1):78-87. PubMed ID: 11792884
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
20. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
Klimiuk PA; Sierakowski S; Chwiećko J
Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
